Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Payables (2016 - 2025)

Historic Payables for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $12.0 million.

  • Heron Therapeutics' Payables rose 1795.25% to $12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.0 million, marking a year-over-year increase of 1795.25%. This contributed to the annual value of $11.7 million for FY2024, which is 26138.89% up from last year.
  • As of Q3 2025, Heron Therapeutics' Payables stood at $12.0 million, which was up 1795.25% from $161.8 million recorded in Q2 2025.
  • Over the past 5 years, Heron Therapeutics' Payables peaked at $161.8 million during Q2 2025, and registered a low of $837000.0 during Q1 2024.
  • Over the past 5 years, Heron Therapeutics' median Payables value was $8.2 million (recorded in 2022), while the average stood at $15.4 million.
  • Per our database at Business Quant, Heron Therapeutics' Payables crashed by 8582.29% in 2023 and then surged by 148266.18% in 2025.
  • Heron Therapeutics' Payables (Quarter) stood at $3.8 million in 2021, then dropped by 15.2% to $3.2 million in 2022, then increased by 0.47% to $3.2 million in 2023, then skyrocketed by 261.39% to $11.7 million in 2024, then rose by 2.63% to $12.0 million in 2025.
  • Its Payables was $12.0 million in Q3 2025, compared to $161.8 million in Q2 2025 and $12.3 million in Q1 2025.